HOME >> MEDICINE >> NEWS
Better survival seen for early breast cancer patients switched from tamoxifen to Aromasin

ATLANTA, June 3, 2006 New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer patients who switched to Aromasin after 2 to 3 years of tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on tamoxifen for a full 5 years of therapy.

"Exemestane is the only anti-hormonal therapy that has been shown to demonstrate improved overall survival over tamoxifen alone," said Lead Investigator Professor Charles Coombes, director of cancer medicine, Imperial College, London. These significant survival benefits were seen in patients who are considered hormone sensitive, which represents 97% of the study population. Although not statistically significant in the intent to treat population, 15% of patients taking Aromasin were more likely to be alive versus those that continued on tamoxifen. These new findings were based on nearly 5 years of follow-up after randomization in the IES trial. IES was a large randomized double blind multinational trial of postmenopausal women with early breast cancer which was designed to compare the clinical benefits of switching 2352 patients to Aromasin after 2 to 3 years of tamoxifen versus continuing 2372 patients on tamoxifen for a full 5 years of therapy. The 5 year follow-up time includes a period of observation lasting over 2 years after completion of all treatment.

Earlier results of the IES trial, which led to US FDA and European regulatory approvals of Aromasin for treatment of early breast cancer, found that postmenopausal hormone receptor positive patients, which represented 85% of all patients in the trial, who switched to Aromasin reduced their risk of breast cancer recurring by 35% versus patients who stayed on tamoxifen for 5 years. At the earlier time point, a difference in overall survival had not been seen.

Breast cancer is one of the most comm
'"/>


3-Jun-2006


Page: 1 2 3

Related medicine news :

1. Better mobility keeps seniors healthier
2. Better insight into brain anatomical structures
3. Better health twice as likely for nonsmokers who live and work with smoking restrictions
4. Better designed roadway intersections can boost older drivers performance
5. Better strategies for osteoporosis prevention and therapy
6. Better review of new technology is needed to reduce health costs
7. Better training needed to reduce emergency caesareans
8. Better after-school snack choices boost nutrition for low-income kids, UC Davis research confirms
9. Outcomes of patients in trials; Better blood pressure treatment; Snake bites, and more
10. Better regulation needed for ethical research in Africa
11. Better procedures needed on care of prisoners in hospitals

Post Your Comments:
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
(Date:12/20/2014)... December 20, 2014 Angeldress.co.uk, the distinguished ... great for worldwide dress fans. The company has recently ... and information. For the holiday season, Angeldress Blog ... special wedding apparel. , Angeldress.co.uk prides itself in offering ... level of service. All the company’s outfits are very ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The aftermath of ... quite a stir, not only in Hollywood, but worldwide. ... 18th , the ripples of that attack are starting a ... jobs at risk. But they are not the only ... could be in for some embarrassing times ahead, agents and ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
Cached News: